Floatz logo

Datopotamab Deruxtecan

Alopecia

Jules Bordet Instituteantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Alopecia cohort.

Asset / SponsorPhaseRating
Trastuzumab Deruxtecan
Jules Bordet Institute
Phase 2CCC
Bimatoprost
Jonsson Comprehensive Cancer Center
N/AD
HUMAN FAECAL MATTER
Chinese University of Hong Kong
N/AD

Same molecule, other indications

Datopotamab Deruxtecan is also rated in:

stomatitisDormant
BB
Indicative ·
65 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
biliary tract cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →